Germany: Reform of European Pharmaceutical Legislation

An Overview of Recent Changes in the Licensing Procedure for Medicinal Products
Last Updated: 4 August 2004
Article by Jochen Eimer

It was only recently that the process of reforming European pharmaceutical legislation within the framework of European Commission proposal ‘Pharma Review 2001’ was finally completed, with the adoption of a pharmaceutical legislation package comprising a new Regulation (EC) No. 726/2004 and two amending Directives 2004/27/EC and 2004/28/EC by the European Parliament and the Council of the European Union on 17 December 2003 and 11 March 2004, respectively.

The main objective of this reform is to improve the current authorisation procedure in a way that strengthens the availability of innovative medicinal products and, at the same time, ensures the right balance between the competitiveness of the pharmaceutical industry, the completion of the single market, and a high level of public health within the enlarged European Union. We will look at the individual pieces of legislation ultimately agreed upon to reach this goal in practice in the course of this article. At the beginning, however, we will briefly introduce the different marketing authorisation procedures for medicinal products available in Europe to provide the reader with a better understanding of the regulatory framework in which the recent changes took place.

Background—European Procedures for Marketing Authorisation

Within the European Union there are three different forms of marketing authorisation procedures —the Centralised Procedure, the Mutual Recognition Procedure and the independent National Procedures. The latter two are also referred to as the Decentralised Procedures.

The Centralised Procedure is currently compulsory for all medicinal products that satisfy the criteria listed in Part A of the Annex to Regulation (EEC) No. 2309/93, i.e., products developed by certain biotechnological processes, and optional for all medicinal products that come under one of the criteria referred to in Part B of that Annex, i.e., certain other innovative products. In both cases, applications for marketing authorisation must be submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). Following the Agency’s scientific evaluation and positive opinion, marketing authorisations will generally be granted by the European Commission after further consultation with the Member States through the relevant standing committee. Marketing authorisations granted under the Centralised Procedure are valid throughout the Community and confer the same rights and obligations in each of the Member States as a national marketing authorisation granted in a particular Member State.

All medicinal products for which the Centralised Procedure is not mandatory may be eligible for national marketing authorisations in one or more of the Member States. If medicinal products are to be authorised in more than one Member State, the marketing authorisations will generally be granted in the Mutual Recognition Procedure. This means that one Member State acts as Reference Member State which—after carrying out a complete assessment of the application—will issue the national marketing authorisation for that Member State. All other Member States in which the medicinal product are to be marketed are referred to as Concerned Member States, all of which will base their respective national marketing authorisation on the mutual recognition of the national marketing authorisation granted by the Reference Member State. That said, the independent National Procedures are generally limited to cases where either a complete review is being undertaken by the Reference Member State in the initial phase of the Mutual Recognition Procedure, or marketing authorisations are sought for one particular Member State only.

Reason for Reform

Under Article 71 of Regulation (EEC) No. 2309/93, which set up the Centralised Procedure for certain medicinal products for human and veterinary use and established the EMEA, the European Commission was asked to report within 6 years after the Regulation’s entry into force in 1995 on the experience of using this new form of centralised marketing authorisation procedure. In its report, the Commission concluded that, whilst the general principle and basic structure of the Centralised and Decentralised Procedure should be maintained, there was nevertheless a need to improve and fine-tune certain details regarding the operation of these authorisation procedures in practice, such as:

  • access to the Centralised Procedure;
  • availability of a fast track procedure;
  • regulatory data protection; and 
  • compassionate use.

The new Regulation and the two amending Directives reflect these initial recommendations by the European Commission, as this article explains.

Extension of the Centralised Procedure

The new legislation extends the current scope of the compulsory Centralised Procedure. Effective 20 November 2005, the Centralised Procedure will become mandatory for all medicinal products for human use containing a new active substance and indicated for the treatment of AIDS, cancer, neurodegenerative disorders and diabetes. It will also apply to medicinal products designated as orphan medicinal products pursuant to Regulation (EC) No. 141/2000. Following an initiative of the European Parliament, with effect from 20 May 2008, the compulsory Centralised Procedure will also cover medicinal products for the treatment of auto-immune diseases and other immune dysfunctions as well as viral diseases.

Marketing authorisations in the optional Centralised Procedure may be granted:

  1. for medicinal products containing new active substances not authorised in the EU on the date of entry into force of the new Regulation;
  2. for medicinal products which the applicants show constitute a significant therapeutic, scientific or technical innovation or that the granting of authorisation in accordance with the new Regulation is in the interests of patients or animal health at the EU level; or
  3. for immunological veterinary medicinal products for the treatment of animal diseases that are subject to EU prophylactic measures.

Procedures to Speed Up the Availability of Medicinal Products

To make certain human and veterinary medicinal products which are of major interest from the viewpoint of public or animal health and in particular because of their therapeutic innovation, available within the shortest possible time, the new Regulation provides for an "Accelerated Assessment Procedure". Once the Committee of the EMEA reviewing the application has accepted the applicant’s request for such a procedure, the time limit for the Committee to deliver its opinion is reduced from 210 days after receipt of a valid application to just 150 days.

Furthermore, the new Regulation enables Member States to make certain medicinal products available on a compassionate use basis before a marketing authorisation has been granted for them, as long as they qualify for the Centralised Procedure and, if no application for marketing authorisation has already been submitted, as long as they are at least undergoing clinical trials. Availability is limited to patients with a chronically or seriously debilitating or life-threatening disease for which satisfactory treatment with an authorised medicinal product is unavailable.

Regulatory Data Protection

One of the most debated issues of the reform was the protection of the pharmacological, toxicological and clinical data contained in the dossier of an original medicinal product against references by generic competitors.

Under the current regime, all medicinal products authorised under the Centralised Procedure benefit from a 10-year period of exclusivity. The same protection period is conferred upon medicinal products authorised in Belgium, Germany, France, Italy, the Netherlands, Sweden, the United Kingdom and Luxembourg, whereas Austria, Denmark, Finland, Greece, Ireland, Iceland, Norway, Portugal and Spain only grant data exclusivity for a period of 6 years.

Despite strong concerns being voiced from the 10 new Member States, who expect a huge negative impact on their national healthcare budgets due to the later availability of generic medicinal products, the new legislation implements a uniform extended period of regulatory data protection in all EU countries. Medicinal products authorised under the Centralised Procedure (both in compulsory and optional) as well as the Decentralised Procedure will now enjoy a period of data protection of 8 years and an additional 2 years of marketing protection. This means that generic manufacturers can submit an application for marketing authorisation 8 years after an originator product is first put on the market, but that the generic product cannot be marketed for a further 2 years after the end of that period. If one or more new therapeutic indications of significant clinical benefit are authorised within the first 8 years of data protection then the protection may be extended by one additional year, up to total of 11 years. For certain veterinary medicinal products, this protection can even add up to an overall period of 13 years.

Validity of Marketing Authorisation

At present, the initial term of validity of a marketing authorisation granted under the Centralised Procedure and in the Decentralised Procedure is 5 years. Whilst this situation will basically not change under the new legislation, a new regime will come into operation for renewals of initial authorisations.

In future, upon expiry of the initial five-year term, the marketing authorisation may be renewed upon request of the marketing authorisation holder, for an generally unlimited period of time. Requests for renewals have to be accompanied by supporting data such as a consolidated version of the file in respect of quality, safety and efficacy, and have to be submitted to the competent authority at least 6 months before the initial marketing authorisation ceases to be valid.

Once a marketing authorisation has been granted, the holder will now have to make use of it because any authorisation not followed by the actual placing on the market of the authorised product within 3 years of its granting will cease to be valid. This will equally apply to authorised products were previously marketed in the authorising Member State but which have not been present on the market for three consecutive years. To this end, the marketing authorisation holder must inform the competent authority of the dates of actual marketing of the medicinal product in the Member States, taking into account the various presentations authorised. Further notification has to be made if the product ceases to be placed on the market, either temporarily or permanently.

Further Changes

As a result of Regulation (EC) No 726/2004 entering into force, the name of the European Agency for the Evaluation of Medicinal Products will be changed to the European Medicines Agency. In addition, the tasks of the EMEA Scientific Committees have been redefined and now reflect to a greater extent a modern, service-oriented approach. In particular, future applicants for marketing authorisations will be able to obtain scientific advice from the Scientific Committees more generally and in greater depth. Further measures have been put in place to allow the development of advice, particularly for small and medium-sized companies.

Next Steps and Strategy

As mentioned above, major parts of the new Regulation will come into force on 20 November 2005. By 30 October 2005, Member States must have implemented Directives 2004/27/EC and 2004/28/EC into their national laws.

Given the particularly crucial issue of regulatory data protection, this time schedule may make it advisable for some manufacturers of innovative medicinal products to reconsider their timing strategies and so delay application for a new medicinal product to enjoy greater protection. This is because the new standards only apply to those medicinal products for which application for marketing authorisation is submitted after the date of entry into force of the new legislation. 

Copyright © 2007, Mayer, Brown, Rowe & Maw LLP. and/or Mayer Brown International LLP. This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

Mayer Brown is a combination of two limited liability partnerships: one named Mayer Brown LLP, established in Illinois, USA; and one named Mayer Brown International LLP, incorporated in England.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions